Warning: mkdir(): Permission denied in /home/virtual/lib/view_data.php on line 87 Warning: chmod() expects exactly 2 parameters, 3 given in /home/virtual/lib/view_data.php on line 88 Warning: fopen(/home/virtual/e-kjs/journal/upload/ip_log/ip_log_2024-07.txt): failed to open stream: No such file or directory in /home/virtual/lib/view_data.php on line 95 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 96 Another Milestone for Spinal Intramedullary Tumor Treatment
Neurospine Search


Neurospine > Volume 19(1); 2022 > Article
Kim: Another Milestone for Spinal Intramedullary Tumor Treatment
I read the article “Glioma Immunotherapy: Advances and Challenges for Spinal Cord Gliomas” with great interest, and I hope that this concept will be another game changer [1].
A spinal intramedullary tumor is a challenging disease due to the difficulty of surgical removal without damaging a functional spinal cord. Even with an experienced hand, dysfunction of the dorsal spinal column could occur due to its location, adhesion, and invasion to the normal spinal cord. When removing an intramedullary spinal cord, we have to continuously trade off between oncological and functional outcomes. There have been several milestones to improve those outcomes [2-5]. I think the first milestone would be an introduction to microsurgery. With the help of better visualization, the tumor could be removed with minimal damage to the spinal cord. However, there was a discrepancy between anatomical and functional outcomes. In this regard, the demand to improve functional outcomes led to the introduction of electrophysiological monitoring during surgery. It is a second milestone. However, in many patients, residual or recurrent tumors are inevitable for functional outcomes. We made efforts to improve oncological outcomes using a lesson from brain tumors. However, chemotherapy or radiotherapy was not as dramatic in controlling the problematic tumor as a brain tumor. It is a time to turn our eyes to a different perspective, and immunotherapy may play there. This paper extensively reviewed the concept, possible candidates, and huddles to overcome them. I hope this paper will intrigue scientists and doctors for this perspective.


Conflict of Interest

The author declare no conflict of interest regarding this manuscript.


1. Grady C, Melnick K, Porche K, et al. Glioma immunotherapy: advances and challenges for spinal cord gliomas. Neurospine 2022;19:13-29.
crossref pmid pmc
2. Lee S, Cho DC, Rhim SC, et al. Intraoperative monitoring for cauda equina tumors: surgical outcomes and neurophysiological data accrued over 10 years. Neurospine 2021;18:281-9.
crossref pmid pmc
3. Vasankari V, Haeren R, Niemelä M, et al. Recovery potential of spinal meningioma patients with preoperative loss of walking ability following surgery - a retrospective single-center study. Neurospine 2022 Jan 17 https://doi.org/10.14245/ns.2142956.478. [Epub].
4. Reznik E, Smith AW, Taube S, et al. Radiation and immunotherapy in high-grade gliomas: where do we stand? Am J Clin Oncol 2018;41:197-212.
5. Liu EK, Sulman EP, Wen PY, et al. Novel therapies for glioblastoma. Curr Neurol Neurosci Rep 2020;20:19.
crossref pmid

Editorial Office
CHA University, CHA School of Medicine Bundang Medical Center
59 Yatap-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13496, Korea
Tel: +82-31-780-1924  Fax: +82-31-780-5269  E-mail: support@e-neurospine.org
The Korean Spinal Neurosurgery Society
#407, Dong-A Villate 2nd Town, 350 Seocho-daero, Seocho-gu, Seoul 06631, Korea
Tel: +82-2-585-5455  Fax: +82-2-2-523-6812  E-mail: ksns1987@gmail.com
Business License No.: 209-82-62443

Copyright © The Korean Spinal Neurosurgery Society.

Developed in M2PI

Zoom in Close layer